Key facts
- This page summarizes Meredith Ian T.'s Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Mar 2022, 16:45.
Meredith Ian T. - 28 Mar 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)
- Reporting relationship
- EVP Global Chief Med Officer
- Issuer ticker
- BSX
- Reported as of
- 28 Mar 2022
- Net transaction value
- -$287,764
- SEC form
- 4
- Accepted by SEC
- 29 Mar 2022, 16:45:32 UTC
- Prior SEC filing
- 02 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Susan Thompson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Meredith Ian T. filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 29 Mar 2022.
Change
- Previous filing in this sequence was filed on 02 Mar 2022.
- Current net transaction value: -$287,764.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BSX
transaction
Common Stock
Sale
- Transaction value
- $287,764
- Shares
- -6,588
- Change %
- -19%
- Price
- $43.68
- Shares after
- 28,082
- Date
- 28 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan.